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Abstract
Dementia associated with the Alzheimer’s disease is thought to be correlated with the conversion of the β − Amyloid (Aβ) peptides from soluble monomers to aggregated oligomers
and insoluble fibrils. We present a discrete-time mathematical model for the aggregation of
Aβ monomers into oligomers using concepts from chemical kinetics and population dynamics. Conditions for the stability and instability of the equilibria of the model are established. A
formula for the number of monomers that is required for producing oligomers is also given.
This may provide compound designers a mechanism to inhibit the Aβ aggregation.
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Introduction
Alzheimer’s disease (AD) is the most cause of dementia and the most prevalent neurodegenerative disorder [1, 2, 3]. It is a progressive degenerative disorder that is age-related and is
characterized by the loss of synapses and neurons from the brain and by the presence of extracellular protein-containing deposits (senile plaques) and intracellular neurofibrillary tangles
[4, 2]. Β − Amyloid is the principal protein component of the extracellular plaques. Aβ is a 39to 43- residue proteolytic product of a parental amyloid precursor protein (APP) that localizes
to the plasma membrane, trans-Golgi network, endoplasmic reticulum (ER) and endosomal,
lysosomal and mitochondrial membranes [5, 6]. Aβ contains sequences from extracellular and
transmembrane regions of the parent protein [7, 8]. The spontaneous conversion of Aβ monomers into febrillar aggregates is found to be associated with the development of AD [9]. In fact,
the neurodegenerative effects of AD are hypothesized to arise from Aβ. This is commonly
known as the amyloid hypothesis, and is the dominant model of AD pathogenesis [10, 11, 5,
12, 13, 14, 15]. Albeit, amounting support from biochemical, genetic, and transgenic animal
studies that supports the amyloid hypothesis, [16, 17, 18, 19, 20], debate over the amyloid
hypothesis remains controversial.
In general, protein aggregation from soluble to non-soluble structures has been linked to be
a causative factor of several diseases, including AD, Parkinson’s disease, Huntington’s disease,
Prion disease, among others [21, 15]. For the case of Aβ linkage to AD, it has been found that
Aβ becomes indeed toxic once aggregated [22, 23, 24, 25, 26]. Furthermore, numerous studies
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show a strong correlation between soluble Aβ oligomer levels and the extent of synaptic loss
[27, 28, 29, 30, 31, 32], further suggesting that the soluble oligomers are the causative agents of
AD [33, 34, 35, 36]. This in turn has motivated several studies aimed at exploiting Aβ aggregation mechanisms and kinetics of Aβ conversion. Especially that synthetic Aβ was found to
spontaneously aggregates into sheet-rich fibrils, resembling those in plaques [5].
Naiki and Nakakuki [37] proposed a simple mathematical model in which fibril elongation
is postulated to occur by reversible addition of monomers to preexisting fibrils. The model,
however, does not explain the generation of new fibrils neither it simulates fibril length. Lomakin [38] proposed a detailed kinetic model in which they postulated that rapid reversible equilibrium between monomers and micelles occurs, followed by spontaneous generation of
nuclei from micelles, in an irreversible process. Fibrils then grew by adding monomers to the
fibril tip or the nucleous. The model accounts for the co-existence of monomers and fibrils
and is capable of predicting fibril evolution (mass and length) in time. However, the experiments leading to the model development were performed in non-physiological conditions (pH
1). Pallitto [3] developed a kinetic model that qualitatively de-scribed Aβ self-association kinetics from the unfolded state. The model incorporated information about mass distribution and
length changes of Aβ and accounted for the co-existence of monomer, dimer, and aggregated
species. The model provided mechanisms for both generation and elongation of fibrils, and
was able to capture all the essential features of the experimental data.
The structure of the Aβ monomer is difficult to characterize due to its tendency to aggregate. Experiments focusing on the understanding of physical structure of Aβ showed that they
are not necessarily homogenous in shape. Filament (3–4 nm in diameter) and fibril (8–10 nm
in diameter) structures have been observed in several electron microscopy and atomic force
microscopy experiments [39, 40, 26]. Furthermore, Malinchik et al. [41] suggested that fibers
are made of three to five laterally associated filaments. Fraser [42] reported on observing amyloid fibers made of five to six globular units, each with 2.5–3 nm in diameter. Finally, Reixach
et al. [43] showed that oligomers are formed from the aggregation of at most six monomers.
Mathematical models of the Aβ kinetics provide a clearer mechanistic understanding of the
amyloid fibril growth, improve our ability to design compounds that alter and modulate fibril
formation, and provide therapeutic potential venues for the AD.
This paper develops a discrete mathematical model for the aggregation of monomers to
oligomers and discusses a mechanism to reduce the production of oligomers. The model is
based on the assumption that soluble Aβ oligomers are the causative agents of AD. First, we
provide a brief review of chemical kinetics and then proceed to develop the discrete model. A
stability analysis follows which determines the aggregation condition. Finally, A formula for
the number of monomers that is required for producing oligomers is provided. In [44], Puri
and Li developed a continuous-time (differential equation) model focusing on the network
cross talk among microglia, neuron, and astroglia, and the corresponding pathological consequence. However, in this work, we take a different approach (discrete) in modeling the aggregation of β − Amyloid into diamers, triamers, etc., and finally into oligomers. The novelty of
our approach is the utilization of ideas from chemical kinetics [45] and population dynamics
[46], to develop a discrete-time model describing this process.

A brief review of chemical kinetics
In chemical kinetics [45], if A is the reactant and B is the product, so that A!B, then the average rate of the reaction describes the change in the concentration of either A or B, and is given
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by,
DA change in number of molectues in A
¼
Dt
change in time

ð1Þ

DB change in number of molectues in B
¼
Dt
change in time

ð2Þ

and

moreover,
DB
¼
Dt

DA
Dt

ð3Þ

Letting Δt = 1, we obtain from (3),
Bðt þ 1Þ

BðtÞ ¼

ðAðt þ 1Þ

AðtÞÞ

ð4Þ

In general, for the reaction,
aA þ bB ! cC þ dD

ð5Þ

where a, b, c, d are the number of molecules of A, B, C, D respectively, we have,
average rate of reaction ¼

1
DA ¼
a

1
DB ¼
b

1
DC ¼
c

1
DD
d

ð6Þ

The reaction rate law expression relates the rate of an elementary reaction to the concentration
of each reactant, that is
average rate of reaction ¼ K:Aa :Bb

ð7Þ

where K is the reaction constant, to be determined experimentally.

The construction of the model: Making oligomers
In its simplest forms, Amyloid formation can be described by protein aggregation, involving
the misfolding of Aβ into soluble and insoluble assemblies [47, 48]. Kinetic studies have suggested that the misfolding of monomeric Aβ has been shown to precede the formation of oligomers, which then serve as seeds for accelerated fibril growth, [49], as illustrated in Fig 1.
The two phases of Amyloid formation are shown: (i) nucleation phase, in which monomers
undergo misfolding and associate to form oligomeric nuclei, and (ii) elongation phase, in
which the oligomeric nuclei rapidly grow by further addition of monomers, forming larger
fibrils. As explained in [48], the nucleation phase occurs gradually and at a slower rate than the
elongation phase which proceeds faster being more favorable. A sigmoidal curve can thus
describe the process. Addition of more monomers (seeds) speeds up the process and induces
faster aggregate formation (blue curve). In contrast, the lack of monomers introduces lag time
and slows down the aggregation process.
We now proceed to the modeling part. We assume that (i) monomers of Aβ aggregate to
form diamers (2 monomers), triamers (3 monomers), . . ., etc. (ii) only monomers aggregate
with diamers, triamers, . . .. (iii) this process of aggregation is irreversible., and finally, (iv) oligomers are formed from the aggregation of six monomers.
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Fig 1. The aggregation of β − Amyloid: From monomers to oligomers. See text for details. Adapted from [48].
https://doi.org/10.1371/journal.pone.0196402.g001

Let M1, M2, M3,. . .,Mn−1, denote the number of monomers, diamers, triamers,:. . ., respectively. It is assumed that n monomers aggregate to make an oligomer as shown in Fig 1. A
mathematical scenario is illustrated in Table 1.
It is important to note that the change ΔM1 for each reaction are different. In Table 1 column 3, we determine the change in this concentration for each reaction. Adding ΔM1 for all
reactions, we get, the overall change for M1:
DM1 ðtÞ ¼

2K1 M1 ðtÞM1 ðt þ 1Þ

K2 M2 ðtÞM1 ðt þ 1Þ

K3 M3 ðtÞM1 ðt þ 1Þ



Which can be written as,
DM1 ðtÞ ¼

2K1 M1 ðtÞM1 ðt þ 1Þ

Pn 1
M1 ðt þ 1Þ i¼2 Ki Mi ðtÞ

ð8Þ

Table 1. Kinetics of monomers aggregation as a function of time.
Reaction
M1 + M1 ! M2

Reaction rate
1
2

DM1 ¼ DM2

Change in ΔM1
ΔM1(t) = −2K1M1(t)M1(t + 1)

M1 + M2 ! M3

−ΔM1 = −ΔM2 = −ΔM3

ΔM1(t) = −K2M2(t)M1(t + 1)

M1 + M3 ! M4

−ΔM1 = −ΔM3 = −ΔM4

ΔM1(t) = −K3M3(t)M1(t + 1)

..
.

..
.

..
.

M1 + Mn−2 ! Mn−1

−ΔM1 = −ΔMn−2 = −ΔMn−1

ΔM1(t) = −Kn−2Mn−2(t)M1(t + 1)

https://doi.org/10.1371/journal.pone.0196402.t001
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Similarly, for i >1 at the ith reaction, we have,
M1 þ Mi ! Miþ1 ; i > 1
therefore, the overall change for Mi, i>1:
DMiþ1 ðtÞ ¼ Ki Mi ðtÞM1 ðtÞ

Kiþ1 M1 ðtÞMiþ1 ðt þ 1Þ

ð9Þ

which can be expanded as,
DM2 ðtÞ ¼ K1 M12 ðtÞ

K2 M1 ðtÞM2 ðt þ 1Þ

DM3 ðtÞ ¼ K2 M1 ðtÞM2 ðtÞ

K3 M1 ðtÞM3 ðt þ 1Þ

..
.

DMn 1 ðtÞ ¼ Kn 2 M1 ðtÞMn 2 ðtÞ

Kn 1 M1 ðtÞMn 1 ðt þ 1Þ

Since monomers are produced by the body, we assume a source function that this is represented by f(M1). Hence the discrete model is finally given by
DM1 ðtÞ ¼ f ðM1 ðtÞÞ

2K1 M1 ðtÞM1 ðt þ 1Þ

DM2 ðtÞ ¼ K1 M12 ðtÞ

Xn 1
M1 ðt þ 1Þ t¼2 Ki Mi ðtÞ

K2 M1 ðtÞM2 ðt þ 1Þ

DM3 ðtÞ ¼ K2 M1 ðtÞM2 ðtÞ

K3 M1 ðtÞM3 ðt þ 1Þ

..
.

DMn 1 ðtÞ ¼ Kn 2 M1 ðtÞMn 2 ðtÞ
h
We now take f ðM1 ðt ÞÞ ¼ dM1 ðt Þ 1

M1 ðtþ1Þ
g

Kn 1 M1 ðtÞMn 1 ðt þ 1Þ

i
. In case of no interaction, the first equation

1 ðtÞ
becomes, M1 ðt þ 1Þ ¼ ðdþ1ÞgM
, which is the popular Beverton-Holt model and is illustrated
gþdM1 ðtÞ

in Fig 2.
The Beverton-Holt model [50] is a discrete-time population model which gives the population size (density) M1(t + 1) as a function of the size (density) of the previous generation M1(t).
Note that (δ + 1) represents the average growth of monomer production with δ>0 and γ is the
carrying capacity. Fig 3 illustrates the growth rate behavior [50, 46].
Using this, we obtain,
M 1 ðt þ 1 Þ ¼
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Fig 2. The cobweb diagram of the Beverton-Holt model of monomer’s production in the absence of aggregation.
The size of monomers increases over time and reaches its carrying capacity γ.
https://doi.org/10.1371/journal.pone.0196402.g002

M2 ðt þ 1Þ ¼

M3 ðt þ 1Þ ¼

M2 ðtÞ þ K1 M12 ðtÞ
1 þ K2 M1 ðtÞ

M3 ðtÞ þ K2 M1 ðtÞM2 ðtÞ
1 þ K3 M1 ðtÞ
..
.

M n 1 ðt þ 1 Þ ¼

Mn 1 ðtÞ þ Kn 2 M1 ðtÞMn 2 ðtÞ
1 þ Kn 1 M1 ðtÞ

ð10Þ



The basic equilibria are the extinction point E = (0,0,. . .,0) and the coexistence point
dg
M  ¼ ðM1 ; M2 ; . . . ; Mn 1 Þ, where M1 ¼ dþngK
; M2 ¼ KK12 M1 ; . . . ; Mn 1 ¼ KKn 1 1 M1 .
1
Moreover, all the points on the surface M1 ¼ 0 are equilibrium points that are of no practical interest since in this case, no chemical reaction is present.

Stability analysis
As mentioned earlier, [43], it is accepted that 6 monomers are needed to aggregate to make

one oligomer. In model (10), let us assume that n = 6. Hence we have the two equilibria E =
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Fig 3. The figure shows the function M2 ¼ MM1 ðtþ1Þ
(on the vertical axis) versus M1(t) (on the horizontal axis). The
1 ðtÞ
growth rate decreases from δ + 1 when M1 is small, to γ and eventually close to zero.
https://doi.org/10.1371/journal.pone.0196402.g003

(0,0,0,0,0), and M  ¼ ðM1 ; M2 ; M3 ; M4 ; M5 Þ. The Jacobian matrix of (10) is now given by
0
1
ðd þ 1Þ 0 0 0 0
B
C
B 0
1 0 0 0C
B
C
B
C
JðE Þ ¼ B 0
0 1 0 0C
B
C
B 0
0 0 1 0C
@
A
0


0 0

0

1



Thus E is unstable, since δ > 0. Next we compute J(M ).
0

M1 ðd þ 2gK1 Þ
M1 K2
M1 K3
B 1
gðd þ 1Þ
ðd þ 1Þ
ðd þ 1Þ
B
B

B
K1 M1
1
B
0
B


1
þ
K
1
þ
K
M
B
2
2 M1
1
B
B
K2 M1
1
0
JðM  Þ ¼ B
B

1 þ K3 M1 1 þ K3 M1
B
B
B
K3 M1
B
0
0
B
1 þ K4 M1
B
B
@
0
0
0

M1 K4
ðd þ 1Þ
0
0
1
1 þ K4 M1
K4 M1
1 þ K5 M1

1
M1 K5
ðd þ 1Þ C
C
C
C
C
0
C
C
C
C
C
0
C
C
C
C
C
0
C
C
C
A
1
1 þ K5 M1



To determine the stability of M , we are going to use the following result due to Gerschgorin
[51].
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Theorem (Gerschgorin)
Let A = (aij) be a k × k matrix. Let Si be the disk in the complex plane with center at aij, and
Pk
radius ri ¼ j6¼i jaij j. Then all eigenvalues of A lie in S ¼ [ki¼1 Si .
M1 ðdþ2gK1 Þ

To apply this result, let us determine the disks a11 ¼ 1
r1 ¼ ja12 j þ ja13 j þ ja14 j þ ja15 j ¼

gðdþ1Þ

ð

,

Pn

1
i¼2

Ki ÞM1
gðd þ 1Þ

We need to show that,
1

M1 ðd þ 2gK1 Þ
gðd þ 1Þ

ð

Pn

1
i¼2

Ki ÞM1
>
ðd þ 1Þ

1

and
1

Pn 1
M1 ðd þ 2gK1 Þ
ð i¼2 Ki ÞM1
þ
<1
gðd þ 1Þ
ðd þ 1Þ

Hence
P5

Ki ðd þ 2gK1 Þ
þ
gðd þ 1Þ
dþ1

M1

i¼2


<2

ð11Þ

and
P5

Ki M1 M1 ðd þ 2gK1 Þ
<
gðd þ 1Þ
dþ1
i¼2

ð12Þ

dg
substituting condition (11) into (12) and letting M1 ¼ dþngK
, we obtain,
1





dg
ð2d þ 4gK1 Þ
d þ 2gK1
¼2
<1
ðd þ 1Þðd þ 6gK1 Þ
g
ðd þ 1Þðd þ 6gK1 Þ

ð13Þ

which is true. Hence, the first condition for the eigenvalue λ1 to be inside the unit disk is
P5
i¼2

K

Ki ¼

d þ 2gK1
g

ð14Þ

M

i 1 1
For 2  i  5; aii ¼ 1þK1i M and ri ¼ 1þK
 we need
iM
1

1

1
K M
þ i 1 1 <1

1 þ Ki M1 1 þ Ki M1

ð15Þ

or,
1 þ Ki 1 M1 < 1 þ Ki M1
or,
Ki

PLOS ONE | https://doi.org/10.1371/journal.pone.0196402 May 23, 2018
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and
Ki 1 M1
>
1 þ Ki M1

1
1 þ Ki M1

Ki 1 M1 >

1

1

Ki M1

1

ð17Þ

ð18Þ

resulting in,
M1 ðKi

1

Ki Þ < 2

ð19Þ

which is true assuming (16).
Hence the condition that all eigenvalues λi, 2  i  n − 1 lie inside the unit disk is Ki−1  Ki,
2in−1
The following theorem summarizes the above stability analysis.

Theorem
The following statements hold true

(i) E is always unstable

(ii) M is stable if
Pn

1
i¼2

Ki <

d þ 2gK1
g

ð20Þ

and Ki−1  Ki for 2  i  n − 1
Now to prevent the aggregation of monomers to oligomers and reduce the toxicity level of
the neuron cells, one should make the system unstable.
This can be accomplished by either (i) using a catalyst that would reduce K1 so that
P5
i¼2

Ki >

d þ 2gK1
g

ð21Þ



and, consequently, the equilibrium point M is unstable, or (ii) using a suppressant to limit the
production of monomers to the effect that the net reproduction rate δ is reduced.
Another interesting problem is to determine exactly how many monomers are needed to
make an oligomer. As mentioned earlier, we followed the literature and assumed that this
number is 6.
dg
However, one may use the formula M1 ¼ dþngK
to find the number of monomers needed to
1
make an oligomer, as
n¼

dðg M1 Þ
K1 M1

ð22Þ

Fig 4 shows the behavior of the number of monomers (n) needed to create an oligomer as a function of K1 (with gamma fixed; blue curve) and as a function of gamma (with K1 fixed; red curve).
As can be seen, to increase n, we can either increase γ or lower K1. By increasing n, one may
reduce the number of oligomers, and consequently, may decrease the likelihood of developing
the Alzheimer’s disease.

Conclusion
AD is an irreversible progressive degenerative disorder that is characterized by the loss of synapses and neurons from the brain and by the presence of extracellular protein containing
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Fig 4. The variation of n, the number of monomer that aggregates to an oligomer, relative to K1 and γ increases or K1 decreases.
https://doi.org/10.1371/journal.pone.0196402.g004

deposits, with β − Amyloid as the principal protein component. The presence of β − Amyloid
is strongly suggested to be a causative of neural degeneration as celebrated by the celebrated
Aβ hypothesis. β − Amyloid monomers aggregate to oligomers and in turn oligomers aggregate to fibrils. In this paper, we have developed a discrete mathematical model for the aggregation of monomers to oligomers. The model is based on the assumption that oligomers are the
toxic stage of the aggregation, and is built using concepts from chemical kinetics and population dynamics. Based on the model, we propose a mechanism to slow down the aggregation
from monomers to oligomers,
X5
i¼2

Ki >

d þ 2gK1
g

Here, γ is the carrying capacity of the β − Amyloid, δ is its growth rate, and Ki is the reaction
constant of i monomers (for instance, K1 is for a monomer, K2 is for a diamer,. . .etc).
Furthermore, we develop an equation for the number of monomers needed to form an oligomer
n¼

dðg M1 Þ
K1 M1

where M1 is the equilibrium state of monomers.
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In this paper, we present a formula for the reduction of the aggregation of monomers to the
toxic oligomers, a process thought to contribute to the development of Alzheimer Disease. To
our knowledge, this is the first discrete mathematical modeling study that combines population dynamics and kinetics principles to develop a prevention mechanism that would potentially reduce the risk of Alzheimer Disease. We note that this is a mathematical model that has
not been tested or implemented in a clinical trial. We derive formulations for critical parameters thought to affect the progression of the AD. Validating the model is beyond the scope of
this paper and is a possible venue for future follow-up work.
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